Imaging as a tumor biomarker in oncology drug trials for lung cancer: The FDA perspective

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 4, 2008, Pages 523-525

  Petrick, N ^a   Brown, D G ^a   Suleiman, O ^a   Myers, K J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; ONCOLOGY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SHORT SURVEY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; NATIONAL INSTITUTES OF HEALTH (U.S.); PHANTOMS, IMAGING; PROGNOSIS; RESEARCH DESIGN; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 56449104997     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.155     Document Type: Short Survey

References (9)

1. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83, 349-353 (2008).
2. US FDA. Challenge and Opportunity on the Critical Path to New Medical Products (U.S. Food and Drug Administration, Rockville, MD, 2004) 〈http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html〉. Accessed 18 May 2008.
3. Altar, C.A. The Biomarkers Consortium: on the critical path of drug discovery. Clin. Pharmacol. Ther. 83, 361-364 (2008).
4. Woosley, R.L. & Cossman, J. Drug development and the FDA's Critical Path Initiative. Clin. Pharmacol. Ther. 81, 129-133 (2007).
5. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. & Thun, M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
6. New Federal Health Initiative to Improve Cancer Therapy: Patients Will Benefit from Rapid Development and Delivery of New Cancer Treatments (US National Institutes of Health, Bethesda, MD, 2006) 〈http://www.cancer.gov/ newscenter/pressreleases/OBQI〉. Accessed 26 June 2008.
7. Clarke, L., Hohl, R. & McLennan, G. Imaging as a biomarker for theory response: cancer as a prototype for the creation of research resources. Clin. Pharmacol. Ther. 84, 433-436 (2008).
8. FDA Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (US Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD, 2007) 〈http://www.fda. gov/CBER/gdlns/clintrialend.htm〉. Accessed 18 May 2008.
9. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).